Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

Recruiting now

Conditions studied: Pancreatic Ductal Adenocarcinoma, Pancreatic Diseases, Pancreatic Elastase 1, Pancreatic Neuroendocrine Tumor, Pancreatitis, Pancreatic Neoplasms

In brief

This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.

Key facts

Study ID

NCT06041009

Run by

Qilu Hospital of Shandong University

People needed

2100

Starts

2023-05-05

Expected to finish

2025-09-30

Last updated by the study team

2024-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Case groups (matching any of the following):
• Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.
• Patients who are the high-risk group of pancreatic cancer.
• Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.
• Patients with other diseases with abnormally elevated CA19-9.
• Control group:
• (1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.

You may not qualify if…

• Patients who are younger than 18 years of age.
• Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.
• Patients who have not signed informed consent.

Where it is running

• Ning Zhong — Jinan, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.